Supply of medicinal products for chemotherapy and drug programs
purchase and delivery of NivolumabThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
Purchase and successive delivery of fedratinibThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
purchase and succession of SiponimodumThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
purchase and succession of OzanimodumThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
purchase and successive delivery of OfatumumabumThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
purchase and successive delivery of AnakinrumThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
Purchase and successive delivery of IdursulfuraseThe quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.
purchase and successive delivery of the medicinal product Subcutaneous immunoglobulin 10%The quality requirements of medicinal products are specified in the Act of 6 September 2001 - Pharmaceutical Law (i.e. Journal of Laws of 2020, item 944), which in Art. Article 1(1)(1) provides that it lays down, m.in, the rules and procedures for the authorisation of medicinal products, taking into account, in particular, the requirements relating to the quality, efficacy and safety of their use.' In addition, the Regulation of the Minister of Health of 9 November 2015 on the requirements of Good Manufacturing Practice (Journal of Laws of 2019, item 728 of późn.zm) specifies in detail the requirements for ensuring the appropriate quality of the medicinal product. In the proceedings in question, the quality requirements of medicinal products have been defined by the Ordering Party by specifying in the description of the subject of the contract which includes, m.in. composition, form and route of administration and unit of measurement.